KPV peptide: the three-residue α-MSH fragment, explained

KPV is about as compact as a research peptide gets: three amino acids, lysine, proline and valine, that map onto residues 11-13 at the C-terminal tail of alpha-melanocyte-stimulating hormone (α-MSH). Its brevity is not a limitation here. It is the whole reason the fragment gets used, and it is why US laboratories studying melanocortin-linked signaling so often reach for KPV rather than the intact hormone.

For laboratory research only. This page explains what KPV is and what the published literature examines. It says nothing about dosing or administration, gives no instructions for use in people or animals, makes no therapeutic claims, and describes a compound that has not been evaluated by the FDA.

Why researchers use the fragment, not the whole hormone

α-MSH is a 13-residue hormone that does several things at once, pigmentation-linked melanocortin signaling included. If your question concerns only a slice of that activity, working with the full hormone is awkward: too many things happen simultaneously to attribute any single effect.

KPV is the C-terminal piece the research keeps. Choosing it over the whole hormone buys three practical things:

• Specificity. It narrows the range of signaling you are actually looking at.
• Synthesis. A three-residue peptide is simple to make and to verify analytically.
• Interpretation. With fewer moving parts, an observed effect is easier to attribute.

None of this is unusual in peptide science. TB-500, for instance, is used as a fragment of thymosin beta-4 rather than the full protein for broadly the same reasons.

What the literature actually examines

It is worth separating what the primary literature examines from what gets claimed downstream, because searches for "KPV peptide benefits" return a great many lists the published work does not support.

The studies themselves are in-vitro and preclinical: cultured cells and animal models. They cluster around melanocortin-linked signaling and the downstream events tied to inflammatory regulation, and the recurring themes are:

• Receptor-dependent mechanisms, signaling routed through melanocortin receptors.
• Receptor-independent mechanisms, activity that does not appear to need receptor binding, a feature of the fragment that draws a lot of discussion.
• Transcriptional responses, shifts in gene expression in cultured cells.
• Stability in solution, how the compound holds up over time.

As with all cell-based work, the numbers move around with concentration, how long cells are exposed, and the model chosen. Culture-dish results do not map cleanly onto whole organisms, and a finding in a dish is not evidence of an effect in a person. The sources below are a useful map of what has and has not been studied.

KPV as a model compound

At only three residues, KPV doubles as a model compound in its own right. Researchers studying short-peptide behavior, degradation kinetics and solution stability often pick it precisely because it is small and well characterized, quite apart from any interest in melanocortin biology. If you are new to the category, what research peptides are sets the context.

KPV inside the KLOW blend

KPV is the "K" in KLOW, the four-part blend rounded out by GHK-Cu, BPC-157 and TB-500, 80mg in total. Pre-combined sets like this let a lab put several distinct-mechanism compounds through one set of conditions instead of preparing four vials separately. To be clear, the blend claims nothing about combined activity: the four are grouped for convenience, nothing more. Our KLOW guide walks through the composition, and GHK-Cu has its own guide.

Supply and format

We list KPV as a ready-mixed 12mg solution rather than a lyophilized powder, so there is no reconstitution to do and no preparation variability to introduce. Every batch carries its own Certificate of Analysis documenting identity and HPLC purity. If you are working back to a concentration from a vial, the peptide calculator does the arithmetic.

How KPV ships in the United States

For US laboratories, KPV is supplied as a pre-mixed 12mg solution prepared under controlled conditions, HPLC-verified, with a batch-specific Certificate of Analysis that reports purity by HPLC and identity by mass spectrometry. Every batch is synthesized in our own UK laboratory, and each US lot is checked in a US laboratory before it goes out, so what ships is made in one place and verified again close to you. Orders are dispatched cold-chain from the warehouse that serves the United States, with tracked delivery across the country next business day, priced in US dollars and payable by Visa, Mastercard or Apple Pay. Store it refrigerated at 2-8°C on arrival, not frozen.

What KPV is not

• It is not an approved medicine in the United States or anywhere else, has not been evaluated by the FDA, and is not supplied for human or veterinary use.
• It is not α-MSH. It is the last three residues of that hormone, deliberately stripped of the rest of its activity.
• It is not a treatment for anything. The benefit lists that circulate online extrapolate well past the in-vitro and preclinical literature.

Dosing and administration

We do not publish dosing, reconstitution-for-use or administration guidance for KPV. It is supplied strictly for in-vitro laboratory research and is not for human or veterinary use, so quantity guidance aimed at a person would be inconsistent with what is actually supplied. Experimental concentrations are specific to the model and endpoint and belong in the primary literature.

Related reading

• What is the KLOW stack? · What is GHK-Cu? · What are research peptides?